SINGH SHAWN (CHIEF EXECUTIVE OFFICER) received a stock award from VISTAGEN THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/3/2023ACC: 0001415889-23-000041
DirectorOfficer· CHIEF EXECUTIVE OFFICER
Since Aug 2018
+5K
Net shares
Net buyer
$438.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
5K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+5K
Price / share
$0.09
Trade value
$438.00
% of position
3.2%
12/30/2022
154K→159K
Total
Net shares
+5K
Net value
$438.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/30/2022 | A · Award | +5K | $0.09 | $438.00 | 3.2% | 154K | 159K |
| Total | +5K | $438.00 | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned626.23K
Total
626.23K indirect626.23K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 626.23K | Indirect |
| Total | 626.23K | 626.23K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported